{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T18:26:10Z","timestamp":1786818370579,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"DOI":"10.1186\/s13044-025-00273-4","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T23:02:54Z","timestamp":1764630174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sirolimus for the treatment of Graves\u2019 orbitopathy"],"prefix":"10.1186","volume":"18","author":[{"given":"Simone","family":"Comi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"273_CR1","doi-asserted-by":"publisher","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol (Lausanne). 2020. https:\/\/doi.org\/10.3389\/fendo.2020.615993.","DOI":"10.3389\/fendo.2020.615993"},{"key":"273_CR2","doi-asserted-by":"publisher","unstructured":"Leo M, Menconi F, Rocchi R, Latrofa F, Sisti E, Profilo MA, Mazzi B, Albano E, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M. Role of the underlying thyroid disease on the phenotype of Graves\u2019 orbitopathy in a tertiary referral center. Thyroid. 2015. https:\/\/doi.org\/10.1089\/thy.2014.0475.","DOI":"10.1089\/thy.2014.0475"},{"key":"273_CR3","doi-asserted-by":"publisher","unstructured":"Lanzolla G, Marin\u00f2 M, Menconi F. Graves disease: latest understanding of pathogenesis and treatment options. Nat Rev Endocrinol. 2024. https:\/\/doi.org\/10.1038\/s41574-024-01016-5.","DOI":"10.1038\/s41574-024-01016-5"},{"key":"273_CR4","doi-asserted-by":"publisher","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marino M, Vaidya B, Wiersinga WM. The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021. https:\/\/doi.org\/10.1530\/EJE-21-0479.","DOI":"10.1530\/EJE-21-0479"},{"key":"273_CR5","doi-asserted-by":"publisher","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","DOI":"10.1056\/NEJMoa1614949"},{"key":"273_CR6","doi-asserted-by":"publisher","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marin\u00f2 M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","DOI":"10.1056\/NEJMoa1910434"},{"key":"273_CR7","doi-asserted-by":"publisher","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021. https:\/\/doi.org\/10.1016\/S2213-8587(21)00056-5.","DOI":"10.1016\/S2213-8587(21)00056-5"},{"key":"273_CR8","doi-asserted-by":"publisher","unstructured":"Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, Tang R, Nguyen QT, Maamari RN, Ugradar S, Hsu K, Karon M, Stan MN. Efficacy and safety of Teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023. https:\/\/doi.org\/10.1210\/clinem\/dgad637.","DOI":"10.1210\/clinem\/dgad637"},{"key":"273_CR9","doi-asserted-by":"publisher","unstructured":"Ugradar S, Parunakian E, Malkhasyan E, Chiou CA, Walsh HL, Joseph Tolentino J, Wester ST, Freitag SK, Douglas RS. The rate of Re-treatment in patients treated with Teprotumumab: a multicenter study of 119 patients with 1 year of follow-up. Ophthalmology. 2025. https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.018.","DOI":"10.1016\/j.ophtha.2024.07.018"},{"key":"273_CR10","doi-asserted-by":"publisher","unstructured":"Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-term efficacy of Teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials. Thyroid. 2024. https:\/\/doi.org\/10.1089\/thy.2023.0656.","DOI":"10.1089\/thy.2023.0656"},{"key":"273_CR11","doi-asserted-by":"publisher","unstructured":"Sears CM, Azad AD, Amarikwa L, Pham BH, Men CJ, Kaplan DN, Liu J, Hoffman AR, Swanson A, Alyono J, Lee JY, Dosiou C, Kossler AL. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. 2022. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.015.","DOI":"10.1016\/j.ajo.2022.02.015"},{"key":"273_CR12","doi-asserted-by":"publisher","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espa\u00f1a Gregori E, Sales-Sanz M. Tocilizumab in Graves orbitopathy study group. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038.","DOI":"10.1016\/j.ajo.2018.07.038"},{"key":"273_CR13","doi-asserted-by":"publisher","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015. https:\/\/doi.org\/10.1210\/jc.2014-3014.","DOI":"10.1210\/jc.2014-3014"},{"key":"273_CR14","doi-asserted-by":"publisher","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015. https:\/\/doi.org\/10.1210\/jc.2014-2572.","DOI":"10.1210\/jc.2014-2572"},{"key":"273_CR15","doi-asserted-by":"publisher","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007. https:\/\/doi.org\/10.1038\/nri2155.","DOI":"10.1038\/nri2155"},{"key":"273_CR16","doi-asserted-by":"publisher","unstructured":"Yan C, Duan RS, Yang H, Li HF, Zou Z, Zhang H, Zhou H, Li XL, Zhou H, Jiao L, Chen J, Yin J, Du Q, Lee M, Chen Y, Chen X, Zhao C. Therapeutic effects of Batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther. 2022. https:\/\/doi.org\/10.1007\/s40120-022-00345-9.","DOI":"10.1007\/s40120-022-00345-9"},{"key":"273_CR17","doi-asserted-by":"publisher","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, Srinivasan A, Hadjiiski L, Jordan D, Bradley EA, Stan MN, Eckstein A, Pitz S, Vorl\u00e4nder C, Wester ST, Nguyen J, Tucker N, Sales-Sanz M, Feldon SE, Nelson CC, Hardy I, Abia-Serrano M, Tedeschi P, Janes JM, Xu J, Vue P, Macias WL, Douglas RS. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, Batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023. https:\/\/doi.org\/10.1210\/clinem\/dgad381.","DOI":"10.1210\/clinem\/dgad381"},{"key":"273_CR18","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA, 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"273_CR19","doi-asserted-by":"publisher","unstructured":"Saxton RA, Sabatini DM. mTOR Signaling in growth, metabolism, and disease. Cell. 2017. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004.","DOI":"10.1016\/j.cell.2017.02.004"},{"key":"273_CR20","doi-asserted-by":"publisher","unstructured":"Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013. https:\/\/doi.org\/10.1038\/nature12122.","DOI":"10.1038\/nature12122"},{"key":"273_CR21","doi-asserted-by":"publisher","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2022. https:\/\/doi.org\/10.1016\/j.cub.2022.01.027.","DOI":"10.1016\/j.cub.2022.01.027"},{"key":"273_CR22","doi-asserted-by":"publisher","unstructured":"Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005. https:\/\/doi.org\/10.1016\/j.cub.2005.02.053.","DOI":"10.1016\/j.cub.2005.02.053"},{"key":"273_CR23","doi-asserted-by":"publisher","unstructured":"Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell. 2014. https:\/\/doi.org\/10.1016\/j.cell.2013.11.049.","DOI":"10.1016\/j.cell.2013.11.049"},{"key":"273_CR24","doi-asserted-by":"publisher","unstructured":"Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin\/TOR signalling network. Nat Cell Biol. 2003. https:\/\/doi.org\/10.1038\/ncb996.","DOI":"10.1038\/ncb996"},{"key":"273_CR25","doi-asserted-by":"publisher","unstructured":"Wang L, Harris TE, Roth RA, Lawrence JC Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007. https:\/\/doi.org\/10.1074\/jbc.M702376200.","DOI":"10.1074\/jbc.M702376200"},{"key":"273_CR26","doi-asserted-by":"publisher","unstructured":"Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt\/PKB substrate PRAS40. Nat Cell Biol. 2007. https:\/\/doi.org\/10.1038\/ncb1547.","DOI":"10.1038\/ncb1547"},{"key":"273_CR27","doi-asserted-by":"publisher","unstructured":"Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008. https:\/\/doi.org\/10.1126\/science.1157535.","DOI":"10.1126\/science.1157535"},{"key":"273_CR28","doi-asserted-by":"publisher","unstructured":"Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex. Genes Dev. 2004. https:\/\/doi.org\/10.1101\/gad.1256804.","DOI":"10.1101\/gad.1256804"},{"key":"273_CR29","doi-asserted-by":"publisher","unstructured":"DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008. https:\/\/doi.org\/10.1101\/gad.1617608.","DOI":"10.1101\/gad.1617608"},{"key":"273_CR30","doi-asserted-by":"publisher","unstructured":"Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012. https:\/\/doi.org\/10.1038\/nature11083.","DOI":"10.1038\/nature11083"},{"key":"273_CR31","doi-asserted-by":"publisher","unstructured":"D\u00fcvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010. https:\/\/doi.org\/10.1016\/j.molcel.2010.06.022.","DOI":"10.1016\/j.molcel.2010.06.022"},{"key":"273_CR32","doi-asserted-by":"publisher","unstructured":"Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016. https:\/\/doi.org\/10.1126\/science.aad0489.","DOI":"10.1126\/science.aad0489"},{"key":"273_CR33","doi-asserted-by":"publisher","unstructured":"Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013. https:\/\/doi.org\/10.1126\/science.1228792.","DOI":"10.1126\/science.1228792"},{"key":"273_CR34","doi-asserted-by":"publisher","unstructured":"Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012. https:\/\/doi.org\/10.4161\/auto.19653.","DOI":"10.4161\/auto.19653"},{"key":"273_CR35","doi-asserted-by":"publisher","unstructured":"Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med. 2008. https:\/\/doi.org\/10.1084\/jem.20071477.","DOI":"10.1084\/jem.20071477"},{"key":"273_CR36","doi-asserted-by":"publisher","unstructured":"Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009. https:\/\/doi.org\/10.1038\/nature08155.","DOI":"10.1038\/nature08155"},{"key":"273_CR37","doi-asserted-by":"publisher","unstructured":"Murooka TT, Rahbar R, Platanias LC, Fish EN. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR\/4E-BP1. Blood. 2008. https:\/\/doi.org\/10.1182\/blood-2007-11-125039.","DOI":"10.1182\/blood-2007-11-125039"},{"key":"273_CR38","doi-asserted-by":"publisher","unstructured":"Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett. 2003. https:\/\/doi.org\/10.1016\/s0014-5793(03)00828-7.","DOI":"10.1016\/s0014-5793(03)00828-7"},{"key":"273_CR39","doi-asserted-by":"publisher","unstructured":"Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W. PtdIns(3, 4, 5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. 2015. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0460.","DOI":"10.1158\/2159-8290.CD-15-0460"},{"key":"273_CR40","doi-asserted-by":"publisher","unstructured":"Xu W, Chen H, Xiao H. mTORC2: a neglected player in aging regulation. J Cell Physiol. 2024. https:\/\/doi.org\/10.1002\/jcp.31363.","DOI":"10.1002\/jcp.31363"},{"key":"273_CR41","doi-asserted-by":"publisher","unstructured":"Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan M, Roux PP, Su B, Jacinto E. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J. 2010. https:\/\/doi.org\/10.1038\/emboj.2010.271.","DOI":"10.1038\/emboj.2010.271"},{"key":"273_CR42","doi-asserted-by":"publisher","unstructured":"Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Vill\u00e9n J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011. https:\/\/doi.org\/10.1126\/science.1199484.","DOI":"10.1126\/science.1199484"},{"key":"273_CR43","doi-asserted-by":"publisher","unstructured":"Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004. https:\/\/doi.org\/10.1016\/j.cub.2004.08.026.","DOI":"10.1016\/j.cub.2004.08.026"},{"key":"273_CR44","doi-asserted-by":"publisher","unstructured":"Singh K, Sun S, V\u00e9zina C. Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action. J Antibiot (Tokyo). 1979. https:\/\/doi.org\/10.7164\/antibiotics.32.630.","DOI":"10.7164\/antibiotics.32.630"},{"key":"273_CR45","doi-asserted-by":"publisher","unstructured":"Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transpl Proc. 2003. https:\/\/doi.org\/10.1016\/s0041-1345(03)00211-2.","DOI":"10.1016\/s0041-1345(03)00211-2"},{"key":"273_CR46","doi-asserted-by":"publisher","unstructured":"Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, Llatj\u00f2s R, Escobar I, Sala-Llinas E, Luburich-Hernaiz P, Dorca J. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulm Med. 2018. https:\/\/doi.org\/10.1186\/s12890-018-0626-4.","DOI":"10.1186\/s12890-018-0626-4"},{"key":"273_CR47","doi-asserted-by":"publisher","unstructured":"Ghosh A, Malaisrie N, Leahy KP, Singhal S, Einhorn E, Howlett P, Cohen NA, Mirza N. Cellular adaptive inflammation mediates airway granulation in a murine model of subglottic stenosis. Otolaryngol Head Neck Surg. 2011. https:\/\/doi.org\/10.1177\/0194599810397750.","DOI":"10.1177\/0194599810397750"},{"key":"273_CR48","doi-asserted-by":"publisher","unstructured":"Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0033626.","DOI":"10.1371\/journal.pone.0033626"},{"key":"273_CR49","doi-asserted-by":"publisher","unstructured":"Yu SY, Liu L, Li P, Li J. Rapamycin inhibits the mTOR\/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac Cardiovasc Surg. 2013. https:\/\/doi.org\/10.1055\/s-0032-1311548.","DOI":"10.1055\/s-0032-1311548"},{"key":"273_CR50","doi-asserted-by":"publisher","unstructured":"Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012. https:\/\/doi.org\/10.1126\/science.1215135.","DOI":"10.1126\/science.1215135"},{"key":"273_CR51","doi-asserted-by":"publisher","unstructured":"Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol. 2013. https:\/\/doi.org\/10.1038\/psp.2013.33.","DOI":"10.1038\/psp.2013.33"},{"key":"273_CR52","doi-asserted-by":"publisher","unstructured":"MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000. https:\/\/doi.org\/10.1016\/s0149-2918(00)89027-x.","DOI":"10.1016\/s0149-2918(00)89027-x"},{"key":"273_CR53","unstructured":"Rapamune Prescribing Information. United States food and Drug administration. Wyeth pharmaceuticals, Inc. 2015 May. Retrieved 28 May 2016."},{"key":"273_CR54","unstructured":"Rapamycin. PubChem compound. National Center for Biotechnology Information. Retrieved 1 August 2016."},{"key":"273_CR55","doi-asserted-by":"publisher","unstructured":"Ji L, Xie W, Zhang Z. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.07.006.","DOI":"10.1016\/j.semarthrit.2020.07.006"},{"key":"273_CR56","doi-asserted-by":"publisher","unstructured":"Luo C, Ye WR, Shi W, Yin P, Chen C, He YB, Chen MF, Zu XB, Cai Y. Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet J Rare Dis. 2022. https:\/\/doi.org\/10.1186\/s13023-022-02266-0.","DOI":"10.1186\/s13023-022-02266-0"},{"key":"273_CR57","doi-asserted-by":"publisher","unstructured":"Wang Z, Guo Y, Li K, Huo Y, Wang S, Dong S, Ma M. Targeting the PI3K\/mTOR pathway in idiopathic pulmonary fibrosis: advances and therapeutic potential. Bioorg Med Chem. 2024. https:\/\/doi.org\/10.1016\/j.bmc.2024.117908.","DOI":"10.1016\/j.bmc.2024.117908"},{"key":"273_CR58","doi-asserted-by":"publisher","unstructured":"Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves\u2019 disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002. https:\/\/doi.org\/10.4049\/jimmunol.168.2.942.","DOI":"10.4049\/jimmunol.168.2.942"},{"key":"273_CR59","doi-asserted-by":"publisher","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6348.","DOI":"10.4049\/jimmunol.170.12.6348"},{"key":"273_CR60","doi-asserted-by":"publisher","unstructured":"Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ. Immunoglobulin G from patients with Graves\u2019 disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-Cell infiltration of the thyroid in autoimmune disease. Endocrinology. 2006. https:\/\/doi.org\/10.1210\/en.2005-1375.","DOI":"10.1210\/en.2005-1375"},{"key":"273_CR61","doi-asserted-by":"publisher","unstructured":"Rotondo Dottore G, Torregrossa L, Lanzolla G, Mariotti S, Menconi F, Piaggi P, Cristofani Mencacci L, Posarelli C, Maglionico MN, Dallan I, Figus M, Nardi M, Marcocci C, Basolo F, M M. Role of the mononuclear cell infiltrate in Graves\u2019 orbitopathy (GO): results of a large cohort study. J Endocrinol Invest. 2022. https:\/\/doi.org\/10.1007\/s40618-021-01692-4.","DOI":"10.1007\/s40618-021-01692-4"},{"key":"273_CR62","doi-asserted-by":"publisher","unstructured":"Zhang M, Chong KK, Chen ZY, Guo H, Liu YF, Kang YY, Li YJ, Shi TT, Lai KK, He MQ, Ye K, Kahaly GJ, Shi BY, Wang Y. Rapamycin improves Graves\u2019 orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.160377.","DOI":"10.1172\/jci.insight.160377"},{"key":"273_CR63","doi-asserted-by":"publisher","unstructured":"Wang Y, Chen Z, Wang T, Guo H, Liu Y, Dang N, Hu S, Wu L, Zhang C, Ye K, Shi B. A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves\u2019 orbitopathy. Cell Mol Immunol. 2021. https:\/\/doi.org\/10.1038\/s41423-020-00615-2.","DOI":"10.1038\/s41423-020-00615-2"},{"key":"273_CR64","doi-asserted-by":"publisher","unstructured":"Roos JCP, Eglitis V, Murthy R. Inhibition of fibrotic contraction by sirolimus (Rapamycin) in an ex vivo model of thyroid eye disease. Ohthalmic Plast Reconstr Surg. 2021. https:\/\/doi.org\/10.1097\/IOP.0000000000001876.","DOI":"10.1097\/IOP.0000000000001876"},{"key":"273_CR65","doi-asserted-by":"publisher","unstructured":"Chang S, Perry JD, Kosmorsky GS, Braun WE. Rapamycin for treatment of refractory dysthyroid compressive neuropathy. Ophthalmic Plast Reconstr Surg. 2007. https:\/\/doi.org\/10.1097\/IOP.0b013e3180500d57.","DOI":"10.1097\/IOP.0b013e3180500d57"},{"key":"273_CR66","doi-asserted-by":"publisher","unstructured":"Roos JCP, Murthy R. Sirolimus (Rapamycin) for the targeted treatment of the fibrotic sequelae of Graves\u2019 orbitopathy. Eye (Lond). 2019. https:\/\/doi.org\/10.1038\/s41433-019-0340-3.","DOI":"10.1038\/s41433-019-0340-3"},{"key":"273_CR67","doi-asserted-by":"publisher","unstructured":"Lanzolla G, Maglionico MN, Comi S, Menconi F, Piaggi P, Posarelli C, Figus M, Marcocci C, Marin\u00f2 M. Sirolimus as a second-line treatment for Graves\u2019 orbitopathy. J Endocrinol Invest. 2022. https:\/\/doi.org\/10.1007\/s40618-022-01862-y.","DOI":"10.1007\/s40618-022-01862-y"},{"key":"273_CR68","doi-asserted-by":"publisher","unstructured":"Comi S, Cosentino G, Lanzolla G, Menconi F, Maglionico MN, Posarelli C, Latrofa F, Rocchi R, Figus M, Santini F, Marin\u00f2 M. Long-term outcome of Graves\u2019 orbitopathy following treatment with sirolimus. J Endocrinol Invest. 2025. https:\/\/doi.org\/10.1007\/s40618-024-02470-8.","DOI":"10.1007\/s40618-024-02470-8"},{"key":"273_CR69","doi-asserted-by":"publisher","unstructured":"Comi S, Cosentino G, Sabini E, Ciampa DA, Menconi F, Maglionico MN, Posarelli C, Latrofa F, Rocchi R, Figus M, Santini F, Marin\u00f2 M. Serum levels of rapamycin predict the response of Graves\u2019 orbitopathy to sirolimus. J Endocrinol Invest. 2025. https:\/\/doi.org\/10.1007\/s40618-025-02567-8.","DOI":"10.1007\/s40618-025-02567-8"},{"key":"273_CR70","doi-asserted-by":"publisher","unstructured":"Lai KKH, Wang Y, Pang CP, Chong KKL. Sirolimus versus mycophenolate mofetil for triple immunosuppression in thyroid eye disease patients with recent-onset intractable diplopia: a prospective comparative case series. Clin Exp Ophthalmol. 2023. https:\/\/doi.org\/10.1111\/ceo.14290.","DOI":"10.1111\/ceo.14290"},{"key":"273_CR71","doi-asserted-by":"publisher","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN. Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association. Thyroid. 2022. https:\/\/doi.org\/10.1089\/thy.2022.0251.","DOI":"10.1089\/thy.2022.0251"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-025-00273-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T23:02:54Z","timestamp":1764630174000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-025-00273-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1186\/s13044-025-00273-4","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}